Read more
4:44 PM · 9 November 2020

Biogen stock plunged 30% after unfavorable FDA decision

-
-
Open account Download free app
Biogen (BIIB.US) shares fell 30% during today 'session after U.S. Food and Drug Administration advisory panel voted against approving company's experimental Alzheimer’s disease drug aducanumab last Friday. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 8-1 against recommending approval of Biogen’s aducanumab. Two other members of the panel voted "undecided." On November 4th aducanumab received overall favorable initial review from the FDA which sparked a historic rally during which company's shares rose 44% to $355.63. However, on Friday the outside panel of experts questioned the drug's effectiveness, dimming prospects it will be approved by the agency. It turned out that the drug didn't perform particularly well in its late-stage clinical program. The advisory committee said the single successful test, along with an earlier-stage study, aren't sufficient to prove aducanumab's effectiveness. Biogen stock was halted on Friday during the meeting.
Biogen (BIIB.US) launched today's session with a massive bearish price gap. If current sentiment prevails, the nearest support at $216.00 could be at risk. On the other hand, should buyers manage to regain control, then nearest resistance lies at $244.45. Source: xStation5
3 February 2026, 7:04 PM

Dailu summary: Sell-off on Wall street 📉 Bitcoin and Ethereum extend downfall in panic

3 February 2026, 6:09 PM

Software stocks in panic mode 📉Will Anthropic AI disrupt tech valuations?

3 February 2026, 5:48 PM

US100 loses 2% 📉

3 February 2026, 3:58 PM

The launch of Xeon 600 and cooperation with SoftBank. Is this a breakthrough for Intel?

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits